ATE421324T1 - Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase - Google Patents
Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinaseInfo
- Publication number
- ATE421324T1 ATE421324T1 AT04718960T AT04718960T ATE421324T1 AT E421324 T1 ATE421324 T1 AT E421324T1 AT 04718960 T AT04718960 T AT 04718960T AT 04718960 T AT04718960 T AT 04718960T AT E421324 T1 ATE421324 T1 AT E421324T1
- Authority
- AT
- Austria
- Prior art keywords
- map kinase
- treat cancer
- diseases related
- isoquinoline derivatives
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000009929 raf Kinases Human genes 0.000 abstract 1
- 108010077182 raf Kinases Proteins 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45362403P | 2003-03-11 | 2003-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE421324T1 true ATE421324T1 (de) | 2009-02-15 |
Family
ID=32990797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04718960T ATE421324T1 (de) | 2003-03-11 | 2004-03-10 | Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1603566B1 (enExample) |
| JP (1) | JP2006519807A (enExample) |
| KR (1) | KR20050108383A (enExample) |
| CN (1) | CN1758910A (enExample) |
| AT (1) | ATE421324T1 (enExample) |
| AU (1) | AU2004218914A1 (enExample) |
| BR (1) | BRPI0408257A (enExample) |
| CA (1) | CA2518530A1 (enExample) |
| DE (1) | DE602004019193D1 (enExample) |
| ES (1) | ES2318276T3 (enExample) |
| HR (1) | HRP20050788A2 (enExample) |
| IS (1) | IS8064A (enExample) |
| MA (1) | MA27724A1 (enExample) |
| MX (1) | MXPA05009687A (enExample) |
| NO (1) | NO20054647L (enExample) |
| PL (1) | PL1603566T3 (enExample) |
| PT (1) | PT1603566E (enExample) |
| RU (1) | RU2325159C2 (enExample) |
| TN (1) | TNSN05223A1 (enExample) |
| TW (1) | TW200501955A (enExample) |
| WO (1) | WO2004080464A1 (enExample) |
| ZA (1) | ZA200506571B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2526285A1 (en) | 2003-05-15 | 2004-12-23 | Arqule, Inc. | Inhibitors of p38 and methods of using the same |
| PE20050952A1 (es) * | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| CA2584368A1 (en) | 2004-10-19 | 2006-04-27 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| WO2006089781A1 (en) * | 2005-02-25 | 2006-08-31 | Novartis Ag | Pharmaceutical combination of bcr-abl and raf inhibitors |
| HRP20110839T1 (hr) * | 2005-07-26 | 2011-12-31 | Sanofi | Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze |
| US8318941B2 (en) | 2006-07-06 | 2012-11-27 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| JP2009077712A (ja) * | 2007-09-11 | 2009-04-16 | F Hoffmann La Roche Ag | Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験 |
| US8758323B2 (en) | 2009-07-30 | 2014-06-24 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| EP2545187B1 (en) | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| CA2816088A1 (en) | 2010-10-28 | 2012-05-03 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| CN103435430B (zh) * | 2013-08-08 | 2015-02-18 | 四川大学 | 一种还原酰胺类化合物的方法 |
| KR102119943B1 (ko) | 2018-05-23 | 2020-06-05 | 주식회사 포스코 | 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치 |
| US20210275516A1 (en) * | 2018-07-02 | 2021-09-09 | Ecole Polytechnique Federale De Lausanne (Epfl) | Lactate enhancing compounds and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| ES2342240T3 (es) * | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
| AR025752A1 (es) * | 1999-09-28 | 2002-12-11 | Bayer Corp | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis |
| WO2001058899A1 (en) * | 2000-02-09 | 2001-08-16 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| US20030078271A1 (en) * | 2001-01-31 | 2003-04-24 | Blackburn Thomas P. | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| ATE497603T1 (de) * | 2001-03-02 | 2011-02-15 | Gpc Biotech Ag | Drei-hybrid-assaysystem |
| CA2471314A1 (en) * | 2001-12-21 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| US7220775B2 (en) * | 2002-08-07 | 2007-05-22 | H. Lundbeck A/S | Compound useful for the treatment of neuropathic pain |
-
2004
- 2004-03-10 KR KR1020057016936A patent/KR20050108383A/ko not_active Ceased
- 2004-03-10 JP JP2006504625A patent/JP2006519807A/ja active Pending
- 2004-03-10 WO PCT/EP2004/002460 patent/WO2004080464A1/en not_active Ceased
- 2004-03-10 EP EP04718960A patent/EP1603566B1/en not_active Expired - Lifetime
- 2004-03-10 RU RU2005131168/04A patent/RU2325159C2/ru not_active IP Right Cessation
- 2004-03-10 CA CA002518530A patent/CA2518530A1/en not_active Abandoned
- 2004-03-10 BR BRPI0408257-5A patent/BRPI0408257A/pt not_active IP Right Cessation
- 2004-03-10 TW TW093106341A patent/TW200501955A/zh unknown
- 2004-03-10 PT PT04718960T patent/PT1603566E/pt unknown
- 2004-03-10 HR HR20050788A patent/HRP20050788A2/xx not_active Application Discontinuation
- 2004-03-10 CN CNA2004800065706A patent/CN1758910A/zh active Pending
- 2004-03-10 DE DE602004019193T patent/DE602004019193D1/de not_active Expired - Lifetime
- 2004-03-10 MX MXPA05009687A patent/MXPA05009687A/es active IP Right Grant
- 2004-03-10 PL PL04718960T patent/PL1603566T3/pl unknown
- 2004-03-10 AU AU2004218914A patent/AU2004218914A1/en not_active Abandoned
- 2004-03-10 ES ES04718960T patent/ES2318276T3/es not_active Expired - Lifetime
- 2004-03-10 AT AT04718960T patent/ATE421324T1/de active
-
2005
- 2005-08-17 ZA ZA200506571A patent/ZA200506571B/en unknown
- 2005-09-09 TN TNP2005000223A patent/TNSN05223A1/en unknown
- 2005-09-23 MA MA28511A patent/MA27724A1/fr unknown
- 2005-10-10 NO NO20054647A patent/NO20054647L/no not_active Application Discontinuation
- 2005-10-10 IS IS8064A patent/IS8064A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004218914A1 (en) | 2004-09-23 |
| TNSN05223A1 (en) | 2007-06-11 |
| RU2005131168A (ru) | 2006-05-27 |
| HRP20050788A2 (en) | 2006-12-31 |
| JP2006519807A (ja) | 2006-08-31 |
| ES2318276T3 (es) | 2009-05-01 |
| TW200501955A (en) | 2005-01-16 |
| EP1603566A1 (en) | 2005-12-14 |
| BRPI0408257A (pt) | 2006-03-07 |
| WO2004080464A1 (en) | 2004-09-23 |
| IS8064A (is) | 2005-10-10 |
| CA2518530A1 (en) | 2004-09-23 |
| EP1603566B1 (en) | 2009-01-21 |
| NO20054647D0 (no) | 2005-10-10 |
| ZA200506571B (en) | 2006-07-26 |
| MXPA05009687A (es) | 2005-10-20 |
| RU2325159C2 (ru) | 2008-05-27 |
| DE602004019193D1 (de) | 2009-03-12 |
| CN1758910A (zh) | 2006-04-12 |
| NO20054647L (no) | 2005-12-09 |
| MA27724A1 (fr) | 2006-01-02 |
| PL1603566T3 (pl) | 2009-07-31 |
| PT1603566E (pt) | 2009-04-27 |
| KR20050108383A (ko) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004019193D1 (de) | Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase | |
| ATE453653T1 (de) | Platinkomplexe zur behandlung von tumoren | |
| BRPI0414716A (pt) | derivados de isoquinilona 1,4-dissubstituìdos como inibidores de raf-cinase úteis para o tratamento de doenças proliferativas | |
| DK1353672T3 (da) | Syntese af 4-amino-thalidomidenantiomerer | |
| ES2176251T3 (es) | Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf). | |
| YU21401A (sh) | Tetrahidropiridoetri | |
| DE60118889D1 (de) | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs | |
| ATE343575T1 (de) | Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz | |
| EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
| WO2003106384A3 (en) | Novel boronic chalcone derivatives and uses thereof | |
| ATE432930T1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
| NO20055741D0 (no) | Nye kjemiske forbindelser | |
| ATE367380T1 (de) | Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate | |
| ATE524181T1 (de) | Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen | |
| ATE427746T1 (de) | 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren | |
| DE60328772D1 (de) | Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen | |
| NO20050640L (no) | Rutenium anticancer komplekser | |
| ATE381568T1 (de) | Pyrano(2,3-c)imidazo(1,2-a)pyridin-derivate zur behandlung von gastrointestinalen erkrankungen | |
| DK1745010T3 (da) | Substituerede cyklohexyl-1,4-diaminderivater | |
| DE50211672D1 (de) | Urokinase-inhibitoren | |
| DE60335980D1 (de) | Verfahren zur herstellung von synthetischen derivaten von dibenzylbutyrolacton-lignanen mit antichagas eigenschaften | |
| DE602004014125D1 (de) | Ruthenium(ii)-komplexe zur behandlung von tumoren | |
| ATE406375T1 (de) | Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate | |
| ATE386748T1 (de) | Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen | |
| DE502004003212D1 (de) | Verbindungen, die faktor viia inhibieren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1603566 Country of ref document: EP |